Back
Innate Pharma SA Quote, Financials, Valuation and Earnings
Sponsored
IPHA
Sponsored
Trump's IRS Hands Massive 'Victory Gift' To 401K Owners
Shield your IRA, 401(k) and pension savings from this coming anti-Trump backlash.
Sell
29
IPHA
Innate Pharma SA
Last Price:
1.67
Seasonality Move:
8.67%
7 Day Trial
ALL ACCESS PASS
$
7
Invest. Do Good. Get Rewarded. Just $0.25/Share!
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.Innate Pharma SA Price Quote
$1.67
-0.02 (12.08%)
(Updated: November 21, 2024 at 5:13 AM ET)
Innate Pharma SA Key Stats
Sell
29
Innate Pharma SA (IPHA)
is a Sell
Day range:
$1.60 - $1.70
52-week range:
$1.29 - $3.15
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
4.62
P/B ratio:
4.01%
Volume:
6.4K
Avg. volume:
11K
1-year change:
-32.85%
Market cap:
$123.9M
Revenue:
$56.2M
EPS:
$-0.45
How Much Does Innate Pharma SA Make?
-
How Much Are Innate Pharma SA's Sales Annually?
IPHA Revenues are $56.2M -
How Much Profit Does Innate Pharma SA's Make A Year?
IPHA net income is -$8.2M
Is Innate Pharma SA Growing As A Company?
Data Unavailable
Innate Pharma SA Stock Price Performance
-
Did Innate Pharma SA Stock Go Up Last Month?
Innate Pharma SA share price went down by -17.17% last month -
Did IPHA's Share Price Rise Over The Last Year?
IPHA share price fell by -32.85% over the past 1 year
What Is Innate Pharma SA 52-Week High & Low?
-
What Is Innate Pharma SA’s 52-Week High Share Price?
Innate Pharma SA has traded as high as $3.15 over the past 52 weeks -
What Is Innate Pharma SA’s 52-Week Low Share Price?
Innate Pharma SA has traded as low as $1.29 over the past 52 weeks
Innate Pharma SA Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Innate Pharma SA?
-
How Much Debt Does Innate Pharma SA Have?
Total long term debt quarterly is $38.1M -
How Much Cash Does Innate Pharma SA Have?
Cash and short term investments quarterly total is $98.4M -
What Is Innate Pharma SA’s Book Value Per Share?
Book value per share is 0.38
Is Innate Pharma SA Cash Flow Positive?
-
What Is IPHA Cash Flow From Operations?
Cash flow from operations (TTM) is -$19.4M -
What Is Innate Pharma SA’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$5.4M -
What Is Innate Pharma SA’s Cash Flow From Investing?
Cash flow from investing (TTM) is $23.5M
Innate Pharma SA Return On Invested Capital
-
Is Management Doing A Good Job?
IPHA return on invested capital is -39.78% -
What Is Innate Pharma SA Return On Assets?
ROA measures how assets are converting to revenues and is -18.89% -
What Is IPHA Return On Equity?
ROE is a measure of profitability and is -72.79%
Innate Pharma SA Earnings Date & Stock Price
-
What Is Innate Pharma SA's Stock Price Today?
A single share of IPHA can be purchased today for 1.69 -
What Is Innate Pharma SA’s Stock Symbol?
Innate Pharma SA trades on the nasdaq under the ticker symbol: IPHA -
When Is Innate Pharma SA’s Next Earnings Date?
The next quarterly earnings date for Innate Pharma SA is scheduled on March 21, 2025 -
When Is IPHA's next ex-dividend date?
Innate Pharma SA's next ex-dividend date is November 21, 2024 -
How To Buy Innate Pharma SA Stock?
You can buy Innate Pharma SA shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Innate Pharma SA Competitors
-
Who Are Innate Pharma SA's Competitors?
Below is a list of companies who compete with Innate Pharma SA or are related in some way:
Innate Pharma SA Dividend Yield
-
What Is IPHA Dividend Yield?
Innate Pharma SA’s dividend yield currently is 0% -
What Is Innate Pharma SA’s Payout Ratio?
Innate Pharma SA’s payout ratio is 0% -
When Did Innate Pharma SA Last Pay A Dividend?
The latest dividend pay date is November 21, 2024 -
What Is Innate Pharma SA’s Dividend Per Share?
Innate Pharma SA pays a dividend of $0.00 per share
Innate Pharma SA Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 0% |
Revenue: | 0% | 0% |
Analyst Recommendations
Buy Recommendations: | 3 |
---|---|
Hold Recommendations: | 1 |
Sell Recommendations: | 0 |
Price Target: | 7.40 |
Upside from Last Price: | 339.04% |